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ABSTRACT
Background. The added value of surgery in breast cancer
patients with pathological complete response (pCR) after
neoadjuvant systemic therapy (NST) is uncertain. The
accuracy of imaging identifying pCR for omission of sur-
gery, however, is insufficient. We investigated the accuracy
of ultrasound-guided biopsies identifying breast pCR
(ypT0) after NST in patients with radiological partial (rPR)
or complete response (rCR) on MRI.
Methods. We performed a multicenter, prospective single-
arm study in three Dutch hospitals. Patients with T1–4(N0
or N ?) breast cancer with MRI rPR and
enhancement B 2.0 cm or MRI rCR after NST were
enrolled. Eight ultrasound-guided 14-G core biopsies were
obtained in the operating room before surgery close to the
marker placed centrally in the tumor area at diagnosis (no
attempt was made to remove the marker), and compared
with the surgical specimen of the breast. Primary outcome
was the false-negative rate (FNR).
Results. Between April 2016 and June 2019, 202 patients
fulfilled eligibility criteria. Pre-surgical biopsies were
obtained in 167 patients, of whom 136 had rCR and 31 had
rPR on MRI. Forty-three (26%) tumors were hormone
receptor (HR)-positive/HER2-negative, 64 (38%) were
HER2-positive, and 60 (36%) were triple-negative. Eighty-
nine patients had pCR (53%; 95% CI 45–61) and 78 had
residual disease. Biopsies were false-negative in 29 (37%;
95% CI 27–49) of 78 patients. The multivariable associated
with false-negative biopsies was rCR (FNR 47%; OR 9.81,
95% CI 1.72–55.89; p = 0.01); a trend was observed for
HR-negative tumors (FNR 71% in HER2-positive and 55%
in triple-negative tumors; OR 4.55, 95% CI 0.95–21.73;
p = 0.058) and smaller pathological lesions (6 mm vs
15 mm; OR 0.93, 95% CI 0.87–1.00; p = 0.051).
Conclusion. The MICRA trial showed that ultrasound-
guided core biopsies are not accurate enough to identify
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breast pCR in patients with good response on MRI after
NST. Therefore, breast surgery cannot safely be omitted
relying on the results of core biopsies in these patients.
INTRODUCTION
With systemic treatments becoming increasingly effec-
tive, the number of breast cancer patients undergoing breast
conserving surgery after neoadjuvant systemic therapy
(NST) has increased, and pathological complete response
(pCR) occurs more frequently.1–3 Previous studies have
demonstrated that excision of the residual disease, rather
than the entire initial tumor bed, does not compromise the
recurrence rate in patients undergoing breast conserving
treatment after NST.4,5 It can thus be questioned as to
whether any surgical resection was needed in patients with
pCR in the surgical specimen.
A major challenge in pursuing a surgery-free treatment
strategy for patients with pCR is the identification of pCR
without surgery. Current imaging modalities such as
ultrasound, MRI, and18F-FDG PET-CT-scan are not suffi-
ciently accurate to identify pCR.6,7 Minimally invasive
biopsies to detect the presence of residual tumor in the
breast after NST have been explored in several pilot
studies.8–14 The primary outcome of these studies was the
false-negative rate (FNR), defined as the proportion of
patients with residual disease in the surgical specimen of
the breast that had tumor-negative biopsies after NST.
Promising FNRs were achieved in some of these studies,
leading to the initiation of new trials with a 10% cut-off for
the FNR of biopsies assessing pCR (see supplemental
Table).8,9,13,14
We designed the MICRA trial (Minimally Invasive
Complete Response Assessment of the breast after NST) to
determine whether ultrasound-guided core biopsies of the
breast are sufficiently accurate to differentiate between
breast pCR and residual disease (irrespective of nodal
status) in patients with a radiological complete or partial
response on MRI.15 Here, we present the results of the
interim analysis.
METHODS
Study Design and Participants
This multicenter, prospective, single-arm study included
women aged 18 years or older with stage I–III invasive
breast cancer of any subtype receiving NST. Key eligibility
criteria were placement of a marker centrally in the tumor
before the start of NST and a radiological complete (rCR)
or partial response (rPR, residual size B 2.0 cm and
C 30% decrease in tumor size) on dynamic contrast-en-
hanced (DCE)-MRI after NST according to RECIST
criteria.16 Exclusion criteria were histopathologically con-
firmed DCIS before the start of NST and a history of
ipsilateral breast surgery and/or radiotherapy. Patients were
enrolled in three Dutch hospitals (the Netherlands Cancer
Institute, Deventer Hospital, and Rijnstate Hospital). The
medical ethical committee of the Netherlands Cancer
Institute approved the conduct of the study.
Procedures
Mammography, ultrasound, and DCE-MRI were used
for assessment of the primary tumor and axillary nodes
prior to NST. Core needle biopsies (14 G) from the primary
tumor were obtained to determine breast cancer subtype
and grade (according to the modified Bloom-Richardson
system) and fine needle aspiration (FNA) was performed of
suspect lymph nodes. Estrogen receptor and progesterone
receptor were defined as positive if expression was C 10%,
and immunohistochemistry assessment of HER2 overex-
pression was regarded as positive if 3 ? or 2 ? with
positive in situ hybridization, according to ASCO-CAP
guidelines. Before the start of NST, the breast lesion was
localized with a marker (e.g., iodine seed, clip, hydro-
marker, twist marker) followed by mammography and/or
ultrasound to confirm adequate position of the marker.
Patients with hormone receptor (HR)-positive/HER2-
negative tumors were treated with four cycles of two-
weekly cyclophosphamide and doxorubicin, followed by
12 weekly administrations of paclitaxel. Patients with tri-
ple-negative tumors in addition received carboplatin
concurrent with paclitaxel. Patients with HER2-positive
tumors received nine cycles of paclitaxel, carboplatin,
trastuzumab, and pertuzumab (PTC-Ptz), or three cycles of
5-fluorouracil, epirubicin, cyclophosphamide, trastuzumab,
and pertuzumab (FEC-T-Ptz), followed by six cycles PTC-
Ptz.2 Patients with cT1N0 HER2-positive disease received
twelve weekly cycles of paclitaxel and trastuzumab. All
patients underwent DCE-MRI before the start and at the
end of NST with a 1.5-T system (in 18 patients, GE
healthcare, Eindhoven, the Netherlands) and a 3.0-T sys-
tem (in 201 patients, Philips Medical Systems, Best, the
Netherlands) using dedicated phased array bilateral breast
coils. Images were acquired in the axial plane with the
patient in prone position. The MRI protocol consists of a
DCE T1-weighted sequence, a diffusion-weighted
sequence, and optionally a fast dynamic sequence as pre-
viously described.15 MRI examinations were assessed by
breast radiologists. Radiological complete response (rCR)
was defined as complete absence of pathological (i.e., non-
physiological) contrast enhancement in the original tumor
area. Radiological partial response was defined as
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0.1–2.0 cm contrast enhancement and C 30% decrease in
tumor size, according to RECIST 1.1 criteria16 (Fig. 1).
Other radiologic features analyzed were presence of non-
mass enhancement and multifocality on MRI, and presence
of calcifications on mammography.
Biopsies and the surgical procedure were performed
within 6 weeks after NST. Specialized breast radiologists
obtained a maximum of eight ultrasound-guided biopsies
of the initial tumor area with a 14-gauge (14-G) automated
needle device and a 22-mm-throw biopsy gun (Bard
Magnum biopsy Instrument, Covington, GA, USA), con-
centrically around a pre-NST placed marker: four central
biopsies close to the marker, and four more peripheral
biopsies. In patients with multifocal or multicentric tumors,
more than one marker may be used to facilitate breast
conserving surgery in patients with good NST response. In
these patients, biopsies were obtained from the index lesion
or from the largest marked residual lesion, and compared
with pathology analysis of this lesion only. To minimize
patient discomfort, all biopsies were performed in the
operating room under general anesthesia. The surgical
procedure was performed immediately thereafter. Breast
and axillary surgery were left to the discretion of the
institute.
Outcomes
The primary outcome of the MICRA trial was the FNR
of the biopsy procedure, i.e., the proportion of patients with
residual disease in the surgical specimen of the breast in
whom the biopsies were tumor-negative. Histopathological
analyses of the biopsies were categorized as (1)
histopathologically representative, containing residual
tumor cells or signs of the former tumor bed, (2) unknown,
containing normal breast, fatty, or connective tissue, and
(3) non-representative, containing small non-assessable
tissue.15 A pathological complete response (pCR) was
defined as absence of invasive and in situ carcinoma in the
breast, irrespective of nodal status (ypT0). Response of the
breast was assessed according to the Pinder classification
system.17,18
Secondary outcome measures were specificity, sensi-
tivity, positive predictive value, and negative predictive
value of the biopsy procedure. In addition, patient, tumor,
FIG. 1 Radiological complete
response on dynamic contrast-
enhanced MRI after
neoadjuvant systemic therapy.
Breast MRI in a patient with
left-sided breast cancer before
the start of neoadjuvant
systemic therapy (A) and after
neoadjuvant systemic therapy
(B). Maximum intensity
projection (MIP) images after
treatment show no pathologic
enhancement in the left breast,
radiologically assessed as a
complete response
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and imaging characteristics were collected to evaluate
correlations with a false-negative outcome.
Statistical Analysis
We hypothesized that the true FNR was 3%. The null
hypothesis was a FNR of 8%. It was calculated that 130
patients with residual disease in the surgical specimen were
sufficient to show, with 80% power, that the FNR would
not exceed 8% using a one-sided binomial test with a
significance a-level of 0.05. Based on published data, a
pCR rate of 65% is expected among patients with a rCR
and a pCR rate of 12% among patients with a rPR.7,19
Therefore, 375 patients with rCR and 150 patients with rPR
would be required. Taking into account an approximate
10% biopsy failure rate due to technical difficulties, we
required inclusion of 575 patients at final analysis.15 An
interim analysis for futility was planned after inclusion of
150 patients with rCR on MRI.
The two-sided 95% confidence intervals for the FNR
and for proportions of patients with pCR were calculated
using the Clopper-Pearson exact method. Patients in whom
biopsies could not be obtained were excluded from
analysis.
Differences between patients with false-negative and
true-positive biopsies were tested using the Kruskal–Wallis
rank sum test, Fisher’s exact test, and Pearson’s Chi
squared test. Subgroup analyses were prespecified for
histopathological classification, Bloom-Richardson grade,
hormone receptor status, tumor size on MRI, presence of
non-mass enhancement or multifocality on MRI, presence
of microcalcifications on mammography, and clinical
tumor and nodal stage. Post-hoc analyses, including size of
the residual lesions at pathology analysis, were also per-
formed. Logistic regression was used to identify factors
associated with a false negative result. Statistical signifi-
cance for comparisons between groups was defined as
p\ 0.05. The conditional power calculations were per-
formed with PASS software version 15.0.4. All other
statistical analyses were done using R (version 3.5.0). This




Between April 2016 and June 2019, we enrolled 219
patients, of which 202 patients fulfilled eligibility criteria.
Protocol violations were identified in 17 patients, mainly
due to missed DCIS in pre-NST obtained diagnostic
biopsies. In 35 patients, post-NST biopsies were not
performed. This was due to non-identification of the mar-
ker in 21 patients, and due to logistic reasons in 14 patients.
Thus, a total of 167 (76%) patients were included for
interim analysis (Fig. 2).
Median age was 49 years (IQR 42–56). Tumor histology
was invasive ductal carcinoma (IDC) in 146 patients,
invasive lobular carcinoma in 14 patients, and other spe-
cial-type carcinomas in 7 patients. Distribution of tumor
subtype by hormone receptor and HER2-expression was
HR-positive/HER2-negative in 43 (26%) patients, HR-
positive/HER2-positive in 41 (24%) patients, HR-negative/
HER2-positive in 23 (14%) patients, and triple-negative in
60 (36%) patients. Mean tumor size on DCE-MRI prior to
NST was 27 mm (IQR 21–40). Fifty percent (84 of 167;
95% CI 42–58) of patients were clinically node-positive
prior to NST. Post-NST MRI showed rCR in 136 of 167
(81%, 95% CI 75–87) patients and rPR in 31 of 167 (19%;
95% CI 13–25) patients. Baseline patient characteristics are
listed in Table 1.
Pathology Analysis
Post-NST, a median of eight (IQR 8–8) 14-G ultrasound
guided biopsies per patient were obtained, followed by
breast conserving surgery in 140 (84%) patients and mas-
tectomy in 27 (16%) patients. Biopsies were representative
in 151 (90%) patients, not representative in eight (5%)
patients, and representativeness was unknown in eight
(5%) patients.
In total, 89 (53%, 95% CI 45–61) of 167 patients had
pCR in the surgical specimen, while 78 had residual dis-
ease. Eighty-one (91%) of the 89 patients with breast pCR
had no axillary metastases (ypT0N0). The pCR rate was
60% (81 of 136) in patients with rCR on MRI and 26% (8
of 31) in patients with rPR on MRI (Table 2).
The False-Negative Rate of the Biopsy Procedure
In 29 of the 78 patients without pCR in the surgical
specimen, the residual disease was not present in the
biopsies. Thus, the FNR of the biopsies assessing pCR was
37% (29 of 78; 95% CI 27–49). Sensitivity of the biopsies
was 63% (49 of 78, 95% CI 51–74), specificity was 100%
(89 of 89, 95% CI 0.96–1), positive predictive value was
100% (49 of 49, 95% CI 0.93–1) and negative predictive
value was 75% (89 of 118, 95% CI 67–83) (Table 3).
Biopsies had been scored as non-representative in two of
29 patients with false-negative biopsies and representa-
tiveness was unknown in four patients.
The FNR differed per response group and tumor sub-
type. In the rCR group, the FNR was 47% (26 of 55; 95%
CI 34–61) and in the rPR group, the FNR was 13% (3 of
23; 95% CI 3–34) (p = 0.005). The FNR was 24% (8 of 34;
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95% CI 11–41) in HR-positive/HER2-negative tumors,
29% (5 of 17; 95% CI 10–56) in HR-positive/HER2-pos-
itive tumors, 71% (5 of 7; 95% CI 29–96) in HR-negative/
HER2-positive tumors, and 55% (11 of 20; 95% CI 32–77)
in triple-negative tumors (p = 0.025).
All characteristics of patients with false-negative biop-
sies and patients with true-positive biopsies are listed in
Table 4. Baseline radiological features (calcifications,
multifocality and non-mass) did not differ between the
groups. Compared with patients that had true-positive
biopsies, patients with false-negative biopsies more often
had HR-negative tumors (55% vs 22%, p = 0.0006), a
higher Bloom-Richardson grade (66% vs 33% grade 3,
p = 0.006), rCR (90% vs 59%, p = 0.005), and less resid-
ual invasive disease and/or DCIS in the specimens [6 mm
(IQR 3–9) vs 15 mm (IQR 9–29), p\ 0.001]. The residual
disease in patients with false-negative biopsies was more
frequently DCIS only (ypTis, 21% vs 4%) than residual
invasive disease and DCIS (14% vs 41%) or invasive dis-
ease only (65% vs 55%) (p = 0.009). In multivariable
analysis, only rCR was significantly associated with false-
negative biopsies (OR 9.81, 95% CI 1.72–55.89; p = 0.01).
A trend was seen for HR-negative tumors and smaller size
of the residual disease (size in mm) (OR 4.55, 95% CI
0.95–21.73; p = 0.058 and OR 0.93, 95% CI 0.87–1.00;
p = 0.051) (Table 5).
Adverse Events
Adverse events related to the biopsy procedure were
observed in 11 of 167 (7%; 95% CI 3–11) patients. In these
patients, the radioactive iodine seed (I-125) used for
localization of the tumor area was accidently removed
during the biopsy procedure. Removal of the iodine seed
led to minor adjustments of the surgical procedure in five
patients with planned lumpectomy: in one patient the
iodine seed was directly replaced by a new iodine seed,
three patients had guided wire localization and in two
patients the local excision was widened.
DISCUSSION
The MICRA trial showed that ultrasound-guided 14-G
core biopsies of the breast failed to detect residual disease
in approximately one-third of patients with a radiological
complete or partial response to NST on DCE-MRI. The
MICRA trial was the first trial to study the accuracy of
MRI and ultrasound-guided biopsies of the breast after
NST to identify pCR of the breast.
Minimally invasive methods aiming to identify patients
with pCR of the breast are currently being investigated by
several groups.9,14,20 The published literature before this
study showed promising results.20 In three smaller pilot
studies with 20 to 50 patients, FNRs of 5% to 26% were
219 patients
Signed informed consent
April 2016 - June 2019
Exclusion 17 patients 
  • Did not meet eligbility criteria
  • DCIS pre-NST (n = 10)
  • History of ipsilateral BC (n = 2)
  • Metastatic disease (n = 2)
  • Progressive disease after rCR (n = 1)
  • >2.0cm MRI enhancement (n = 2)
Exclusion 35 patients 
No MICRA biopsies performed
  • Logistic issues (n = 14)
  • Non-identification marker (n = 21)
167 patients
included for analysis
  • Group 1: rCR (n = 136)
  • Group 2: rPR (n = 31) 
FIG. 2 Flowchart. Patient










Complete response MRI Partial response MRI Total
(n = 136) (n = 31) (n = 167)
Age 48 (42–56) 50 (43–56) 49 (42–56)
Clinical tumor stage
T1 32 (24%) 4 (13%) 36 (21%)
T2 87 (64%) 20 (65%) 107 (64%)
T3 17 (12%) 6 (19%) 23 (14%)
T4 0 1 (3%) 1 (1%)
Clinical nodal stage
N? 68 (50%) 16 (52%) 84 (50%)
Imaging features
Multifocal 31 (23%) 9 (29%) 40 (24%)
Non-mass 27 (20%) 6 (19%) 33 (20%)
Calcifications 36 (27%) 9 (29%) 45 (27%)
Tumor size (mm) 27 (20–40) 27 (22–40) 27 (21–40)
Histology
Ductal 121 (89%) 25 (81%) 146 (88%)
Lobular 10 (7%) 4 (13%) 14 (8%)
Other 5 (4%) 2 (6%) 7 (4%)
Tumor subtype
HR ?/HER2 - 32 (24%) 11 (35%) 43 (26%)
HR ?/HER2 ? 36 (26%) 5 (16%) 41 (24%)
HR -/HER2 ? 21 (15%) 2 (7%) 23 (14%)
Triple-negative 47 (35%) 13 (42%) 60 (36%)
Tumor grade
Grade 1 7 (5%) 0 7 (4%)
Grade 2 41 (30%) 15 (48%) 56 (34%)
Grade 3 80 (59%) 15 (48%) 95 (57%)
Unknown 8 (6%) 1 (3%) 9 (5%)
Data are median (IQR) or n (%). All baseline characteristics were assessed before administration of
neoadjuvant systemic therapy. Calcifications were assessed on mammography, other imaging features were
assessed on MRI
TABLE 2 Pathological response assessment by radiological response group
Complete response MRI (n = 136) Partial response MRI (n = 31) Total (n = 167)
Pathological response surgical specimen
No residual carcinoma (1i) 81 (60%) 8 (26%) 89 (53%)
No residual invasive but DCIS (1ii) 8 (6%) 0 8 (5%)
Minimal residual disease,\ 10% (2i) 31 (23%) 8 (25%) 39 (23%)
10-50% of tumor remaining (2ii) 11 (8%) 12 (39%) 23 (14%)
[50% of tumor remaining (2iii) 3 (2%) 3 (10%) 6 (4%)
No evidence of response (3) 1 (1%) 0 1 (1%)
Only LVSI present 1 (1%) 0 1 (1%)
Pathological response biopsies
Tumor-negative 107 (79%) 11 (35%) 118 (71%)
Tumor-positive 29 (21%) 20 (65%) 49 (29%)
Data are n (%). LVSI, lymphovascular invasion
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achieved.9,13,14 A larger multicenter exploratory analysis of
164 patients performed by the German Breast Group
demonstrated an overall FNR of 49%. In this study, not all
patients had a pre-NST placed marker (63%) and biopsy
methods were not standardized.8 A post hoc analysis in 16
patients with mammographic-guided vacuum-assisted
biopsies (VAB) found a FNR of 0%. In the pilot study
performed by the University of Heidelberg, the FNR was
lowered from 26% to 5% when patients in whom biopsies
showed neither tumor cells nor (signs of) the initial tumor
bed at histopathological analysis were excluded.14 None of
these studies used DCE-MRI to select patients with
response, as we did in the MICRA trial.




Biopsies Residual disease in surgical specimen
No (n = 89) Yes (n = 78)
rPR rCR Total rPR rCR Total
Tumor-neg 8 (9%) 81 (91%) 89 (100%) 3 (4%) 26 (33%) 29 (37%)
Tumor-pos 0 0 0 20 (26%) 29 (37%) 49 (63%)
Total 8 (9%) 81 (91%) 89 (100%) 23 (29%) 55 (71%) 78 100%)
Data are n (%). rCR, radiologic complete response on MRI. rPR, radiologic partial response on MRI
TABLE 4 Characteristics and
MICRA assessment in patients
with residual disease
False-negative biopsies (n = 29) True-positive biopsies (n = 49) P - value*
Imaging features pre-NST
Tumor size (mm) 25 (20–31) 32 (23–58) 0.028
Multifocal 5 (17%) 18 (37%) 0.078
Non-mass 7 (24%) 14 (29%) 0.794
Calcifications 12 (41%) 20 (41%) 1.000
Histology pre-NST
Ductal 26 (90%) 39 (80%) 0.423
Lobular 3 (10%) 7 (14%)
Other 0 3 (6%)
Tumor subtype pre-NST
HR ?/HER2 - 8 (28%) 26 (53%) 0.025
HR ?/HER2 ? 5 (17%) 12 (25%)
HR -/HER2 ? 5 (17%) 2 (4%)
triple-negative 11 (38%) 9 (18%)
Tumor grade pre-NST
Grade 1 1 (3%) 3 (6%) 0.006
Grade 2 7 (24%) 29 (59%)
Grade 3 19 (66%) 16 (33%)
Unknown 2 (7%) 1 (2%)
Radiological response 0.005
Complete 26 (90%) 29 (59%)
Partial 3 (10%) 20 (41%)
Pathology post-NST
Tumor size (mm) 6 (3–9) 15 (9–29) \0.001
DCIS or invasive carcinoma
No DCIS 19 (65%) 27 (55%) 0.009
DCIS and invasive 4 (14%) 20 (41%)
DCIS only 6 (21%) 2 (4%)
*Kruskal–Wallis rank sum test, Fisher’s exact test. Data are median (IQR) or n (%). NST, neoadjuvant
systemic therapy. All baseline characteristics were assessed before administration of neoadjuvant systemic
therapy. Calcifications were assessed on mammography, other imaging features were assessed on MRI
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Updated results including a multi-institutional pooled
analysis (MDACC, Seoul National University Hospital21
and the Royal Marsden Hospital22), results of the
RESPONDER trial23 (NCT02948764, University of Hei-
delberg), and results of the NRG-BR005 trial10 (NRG
Oncology) were recently presented.24–26 The multi-insti-
tutional pooled analysis included patients with a partial or
complete radiological response on ultrasound, mammog-
raphy, or MRI, of which 51% had pCR in the surgical
specimen.24 Vacuum-assisted biopsies (86%) or core-cut
biopsies (14%) were performed under ultrasound (78%) or
stereotactic (22%) guidance at which a median of six
(2–18) 10-G (7–14) biopsies were obtained. The overall
FNR was 19% in 159 patients. Post-hoc analysis of patients
with a residual imaging abnormality of B 2 cm who had at
least six image-guided representative VABs showed a FNR
of 3% (n = 76).24
In the RESPONDER trial23, 398 patients were evaluated
at interim analysis in which a median of seven 7- to 8-G
VABs per patient had been obtained. The FNR was 18%:
residual disease was missed in 37 of 208 patients without
pCR in the surgical specimen.25
The NRG-BR005 trial assessed the accuracy of six to
eight 11-G biopsies in patients with ductal carcinoma and a
clinical (near) complete response with tri-modality imaging
after NST:\ 1-cm residual mass on mammography (no
calcifications),\ 2-cm residual mass on ultrasound, no
rapid rise or washout kinetics on a 1.5-T post-NST MRI.10
At the planned interim analysis, 36 out of 98 evaluable
patients had residual disease at surgery, of which 18
patients were not correctly identified by post-NST biopsies
(FNR of 50%).26
Compared with the RESPONDER trial and the multi-
institutional pooled analysis, we found a relatively high
FNR for biopsies detecting residual disease. Key differ-
ences in the study designs were patient selection criteria
TABLE 5 Predictive factors
for false negative MICRA
biopsies (n = 78)
Univariable Multivariable
OR 95% CI P - value OR 95% CI P - value
Imaging features pre-NST
Tumor size (mm) 0.98 0.95–1.00 0.066 0.98 0.94–1.01 0.23
Multifocal 0.36 0.12–1.11 0.074
Non-mass 0.80 0.28–2.28 0.67
Calcifications 1.02 0.40–2.60 0.96
Histology pre-NST
Ductal 1
Lobular 0.64 0.15–2.72 0.55
Other 0.00 0.00–Inf. 0.99
HR C 10% pre-NST
Positive 4.25 1.58–11.48 0.0043 4.55 0.95–21.73 0.058
Subtype pre-NST
HR ?/HER2 - 1
HR ?/HER2 ? 1.35 0.37–5.02 0.65
HR -/HER2 ? 8.12 1.31–50.21 0.024
triple-negative 3.97 1.21–12.99 0.023
Radiological response
Partial 1
Complete 5.98 1.59–22.46 0.008 9.81 1.72–55.89 0.01
Pathology post-NST
Tumor size (mm) 0.88 0.81–0.95 0.0006 0.93 0.87–1.00 0.051
DCIS or invasive carcinoma
No DCIS 1
DCIS and invasive 0.28 0.08–0.97 0.044 0.51 0.12–2.11 0.35
DCIS only 4.26 0.78–23.44 0.095 2.39 0.23–24.37 0.46
Univariable and multivariable logistic regression. HR, hormone receptor expression; NST, neoadjuvant
systemic therapy. All baseline characteristics were assessed before administration of neoadjuvant systemic
therapy. Calcifications were assessed on mammography, other imaging features were assessed on MRI
3250 A. A. van Loevezijn et al.
and biopsy technique. The MICRA trial and the NRG-
BR005 trial were the only trials that used DCE-MRI to
select patients with therapy response. The NRG-BR005
trial, however, only assessed therapy response on post-NST
MRI, whereas both pre- and post-NST MR-images were
used in the MICRA trial for adequate response evaluation.
As DCE-MRI is more accurate in selecting patients with a
(near) pCR compared with conventional imaging, the
proportion of patients with substantial residual disease in
the studies that used conventional imaging for response
monitoring might be higher, which will lower the reported
FNR.
We found a significantly higher FNR in patients with no
rCR on MRI than in patients with residual enhancement
(47% vs 13%). Patients with false-negative biopsies had
less residual disease in the surgical specimens than patients
with true-positive biopsies, and tumors were more often
triple-negative and HR-negative/HER2-positive, which are
the subtypes that respond well to NST. Hence, these factors
that are predictive for a false-negative outcome represent
the same causal mechanism: sampling errors occur more
frequently in patients with minimal residual disease after
NST.
The results the MICRA trial and those of the previous
studies emphasize that current imaging modalities,
including MRI, are not accurate enough to identify patients
with pCR for omission of surgery.6,7 We found residual
disease in the surgical specimens of 40% of patients with
rCR. In the patients with rPR, 26% did achieve pCR at time
of surgery.
One major difference between the previous studies
mentioned and the MICRA study is the quantity of tissue
obtained and examined with biopsies. In the MICRA trial
core biopsies were performed, whereas vacuum-assisted
biopsies were used in most other trials. With 9-G to 10-G
vacuum-assisted biopsies, approximately 7 times as much
tissue per biopsy is obtained compared with 14-G core
needle biopsies, making assessment more reliable.27,28
However, VAB procedures are also associated with more
patient discomfort and may be associated with more severe
bleeding events.29
Another limitation of the MICRA trial was that all
biopsies were obtained immediately before breast surgery
in the operating room, with the patient under general
anesthesia. This procedure minimized patient discomfort,
but most likely affected the accuracy of the biopsies. The
ultrasound equipment used for the biopsy procedure in the
operating room was sometimes inferior to that of the
radiology department. Optimal positioning of the patient
under general anesthesia in an operating room was more
difficult compared with the normal setting in the radiology
department, resulting in more difficult biopsy angles.
However, biopsies were not performed if the marker could
not be visualized during the procedure (21 patients) and
parts of the (former) tumor area were seen in at least one of
the biopsies obtained in almost all patients.
In 89% of all patients, at least eight biopsies could be
obtained. Only six (4%) patients underwent fewer than six
biopsies. Representativeness of the biopsies was marked as
‘‘unknown’’ (i.e., sufficient material for analysis, but no
signs of therapy response or tumor) in eight (5%) patients.
In four of these patients, residual disease was found in the
surgical specimen. Another eight patients were found to
have insufficient biopsy specimens for a pathological
diagnosis, of which two patients had residual disease.
Excluding these patients from the analysis, however, would
not have resulted in a significantly improved FNR (32% vs
37%).
The ultimate aim of the MICRA trial was to develop an
accurate minimally invasive method that would identify
pCR in patients with a radiological response and thereby
potentially allow omission of surgery of the breast in these
patients. At the same time, it is important to accurately
identify patients who do not achieve pCR, as patients with
residual disease after NST have a significantly worse
prognosis and may benefit from additional systemic treat-
ment.30–32 In addition, although the correlation is strong,
pCR of the breast (ypT0) does not entirely exclude the
presence of lymph node metastases (ypN ?).33 Several
studies are currently investiagting the de-escalation of
axillary surgery after NST.34,35 If breast surgery after NST
in patients with pCR could be omitted in the near future,
simulteneous de-escalation of axillary surgery will be
essential.
The optimal cut-off value for the FNR of biopsies (and
type and extent of the errors) identifying pCR for a clini-
cally acceptable recurrence rate, is yet unknown.
Investigators from the MDACC have already started a trial
(NCT02945579) in which breast surgery is omitted in early
stage triple-negative or HER2-positive breast cancer
patients who have at least 12 tumor-negative VABs. The
primary outcome is 5-year locoregional recurrence-free
survival.20
Although the minimally invasive method developed in
the MICRA trial may not be used for omission of surgery,
the interim results contribute to the development of more
accurate methods for detection of pCR in patients with an
excellent response on MRI after NST. The risk of sampling
errors in patients who are most likely to have limited
residual disease after NST may be reduced by obtaining
larger, vacuum-assisted biopsies under optimal conditions
in the radiology department. The development of non-in-
vasive response prediction models incorporating
biomarkers and MRI radiomics using machine-learning, on
the other hand, may eventually outperform minimally
invasive pCR detection methods. Regardless of the
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methods used to identify pCR, it will be essential to decide
to what extent a possibly increased risk of local recurrence
outweighs the benefits of elimination of breast surgery. We
will continue to investigate minimally invasive techniques
predicting pCR to ultimately achieve an operation-free
treatment strategy for patients with pCR after NST.
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